Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

227 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why DexCom (DXCM) Shares Are Trading Lower Today

September 19, 2025 at 12:11 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DXCM Cover Image

What Happened?

Shares of medical device company DexCom (NASDAQ: DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring device, questioned its accounting, and highlighted an executive exodus.

The report claimed that complaints about the G7 device led to the creation of a Facebook group that attracted over 58,000 members in just over a year. Hunterbrook asserted that some doctors stopped prescribing the G7 due to "disproportionate sensor inaccuracies, repeated device failures, connectivity issues, and problems with the adhesive." The short seller also raised flags about DexCom's accounting, suggesting the firm used aggressive tactics to surpass second-quarter earnings estimates. Adding to the pressure, the report noted the recent unexpected departure of its long-serving CEO, Kevin Sayer. Hunterbrook Capital confirmed it held a short position in DexCom shares.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy DexCom? Access our full analysis report here, it’s free.

What Is The Market Telling Us

DexCom’s shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock gained 0.4% on the news that the company announced it would present new product features and positive clinical data at the European Association for the Study of Diabetes (EASD) 2025 conference. The medical device maker planned to unveil its new "Smart Basal" module, an integrated system designed to make basal insulin management easier for users, currently under review by the FDA and for a CE mark. Additionally, Dexcom planned to present new data reinforcing that its continuous glucose monitor (CGM) use reduced acute diabetes events and neonatal complications linked to gestational diabetes more effectively than traditional fingersticks.

DexCom is down 12.1% since the beginning of the year, and at $69.01 per share, it is trading 24% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $704.69.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article